1 hour ago
2
James Brumley, The Motley Fool
Sat, June 6, 2026 astatine 12:52 PM CDT 6 min read
If you support regular tabs connected pharmaceutical elephantine Pfizer (NYSE: PFE), past you cognize it hasn't yet restored the gross mislaid owed to the wind-down of the COVID-19 pandemic; the satellite conscionable doesn't request its vaccine (Comirnaty) oregon its corruption attraction (Paxlovid) arsenic overmuch arsenic it did successful 2022, erstwhile the company's apical enactment surged to conscionable implicit $100 billion. Last year's reported gross was lone $62.6 billion.
You whitethorn besides cognize that Pfizer's top-selling drugs, similar the humor thinner Eliquis and cancer treatments Ibrance and Xtandi, volition suffer their patent extortion adjacent year, portion the patent for its pneumonia vaccine Prevnar 13 is adjacent nearer its end. These 3 drugs unsocial accounted for implicit $20 cardinal of 2025 revenue.
Will AI make the world's archetypal trillionaire? Our squad conscionable released a study connected the 1 little-known company, called an "Indispensable Monopoly" providing the captious exertion Nvidia and Intel some need. Continue »
Connect the dots: Investors disquieted that Pfizer whitethorn not beryllium capable to proceed paying its dividend aren't unwarranted successful their concern. Shares person performed accordingly.
A caller woody struck with China-based biopharma outfit Innovent Biologics (OTC: IVBXF), however, should alleviate astatine slightest immoderate of this worry. And it should easiness astir of the concerns income investors person close now, if this concern serves arsenic a exemplary for aboriginal ones.
Taking the evident steps
It's not arsenic if Pfizer has been ignoring its march toward immoderate cardinal patent cliff, for the record. It's been acting. In November 2025, the drugmaker completed its acquisition of Metsera, garnering its anti-obesity cause candidates. In 2023, it shelled retired $43 cardinal for Seagen, bringing a fistful of promising crab drugs to the table. The 2022 purchases of Global Blood Therapeutics, Biohaven Pharmaceutical Holding, and ReViral began the caller refill of the company's pipeline and portfolio.
And there's assurance successful these acquisitions. With plans to commencement astir 20 pivotal cause trials this year, CEO Albert Bourla commented during past month's first-quarter net league call: "Our caller colony agreements resolving infringement of patent related to Vyndamax [for the attraction of transthyretin-mediated amyloid cardiomyopathy] person the imaginable to alteration the maturation illustration of the institution importantly post-2028. This gives america greater assurance that starting successful 2029, we volition participate a five-year play of high-single-digit gross CAGR [compound yearly maturation rate]."
.png)
English (CA) · 
English (US) · 
Spanish (MX) ·